Lowest Price Guaranteed From USD 4,799
The ocular drug delivery system market is estimated to be worth $465 million in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 15% during the forecast period. According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented.
It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss.
Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.
Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices for ophthalmic route, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of ophthalmologic medications and eye drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in ocular drug delivery system market. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady market growth during the forecast period.
Examples of key companies engaged in ocular drug delivery system market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Alimera Sciences, Bausch and Lomb, EyePoint Pharmaceuticals, Genentech, Glaukos, Neurotech Pharmaceuticals and Ocular Therapeutix. This market report includes an easily searchable excel database of all the companies providing ophthalmic / ocular drug delivery devices, worldwide.
Several recent developments have taken place in the field of ocular drug delivery system market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Ocular Drug Delivery System Market by Type of Drug Delivery Device (Implants, Inserts and Punctal Plugs), Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet Age-related Macular Degeneration, Retinal Diseases, Neovascular Age-Related Macular Degeneration and Others), Type of Product (Biodegradable and Non-biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the ocular drug delivery system market. The market research report features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the market research report includes:
The key objective of ocular drug delivery system market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for ocular drug delivery system market during the forecast period. Additionally, it features market size projections for the overall ocular drug delivery system market, wherein both the current and upcoming opportunity is segmented across [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indications (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others), [C] type of product (biodegradable and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in ocular drug delivery system market. The market research report features detailed transcripts of interviews held with the following individuals: